logo

For the Inventor, By the Inventor

Pittsburgh, PA, United States of America

Mitchell P Fink

This inventor holds 15 USPTO granted patents and 4 published patent applications and 1 EPO patent, primarily in Inflammation Treatment. Top assignees: University of Pittsburgh, The Feinstein Institutes for Medical Research, The General Hospital Corporation. Active years: 2005-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mitchell P Fink. Retrieved from https://idiyas.com/inventor/mitchell-p-fink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 46.7


Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 106(Granted Patents)


Location History:

  • Pittsburgh, PA (US) (2005 - 2016)
  • Los Angeles, CA (US) (2014 - 2017)

Company Filing History:

goldMedal14 out of 1,963 
 
University of Pittsburgh
 patents
silverMedal5 out of 165 
 
The Feinstein Institutes for Medical Research
 patents
bronzeMedal4 out of 3,079 
 
The General Hospital Corporation
 patents
4. 1 out of 539 
 
Beth Israel Deaconess Medical Center, Inc.
 patents
5. 1 out of 21 
 
North Shore-Long Island Jewish Research Institute
 patents
6. 1 out of 4 
 
Xanthus Life Sciences, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2005-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Sorbent Polymer
Mitochondria Targeting
HMGB1
Anti-Inflammatory
Cytokine-Mediated
Ischemia Reperfusion
Electron Scavengers
Pyruvate Derivatives
Systemic Inflammation
Therapeutic Agents
Fragment Use
Polypeptides
15 patents (USPTO):Explore Patents
1. 9603807 - Enteral administration of sorbent polymer for treatment and prophylaxis of inflammation (2017-03-28),
2. 9402839 - Selective targeting agents for mitochondria (2016-08-02),
3. 9006186 - Selective targeting agents for mitochondria (2015-04-14),
4. 8647666 - Administration of an adsorbent polymer for treatment of systemic inflammation (2014-02-11),
5. 8501173 - Antibodies to high mobility group-1(HMGB1) B-box polypeptides (2013-08-06),
6. 8487079 - Use of mitochondria-targeted electron scavengers as anti-inflammatory agents (2013-07-16),
7. 7897569 - Use of HMGB fragments as anti-inflammatory agents (2011-03-01),
8. 7829097 - Use of HMGB1 for protection against ischemia reperfusion injury (2010-11-09),
9. 7749959 - Use of HMGB fragments as anti-inflammatory agents (2010-07-06),
10. 7718603 - Selective targeting agents for mitochondria (2010-05-18),
11. 7528174 - Selective targeting agents for mitochondria (2009-05-05),
12. 7332479 - [object Object] (2008-02-19),
13. 7304034 - Use of HMGB fragments as anti-inflammatory agents (2007-12-04),
14. 6943190 - Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions (2005-09-13),
15. 6846842 - Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion (2005-01-25),

Title: The Innovative Contributions of Mitchell P. Fink

Introduction

Mitchell P. Fink is a prominent inventor based in Pittsburgh, PA, known for his significant contributions to medical research and innovation. With a total of 15 patents to his name, Fink has made strides in developing novel therapeutic methods and compositions aimed at improving patient outcomes.

Latest Patents

Among his latest patents, Fink has developed a method for enteral administration of a sorbent polymer for the treatment and prophylaxis of inflammation. This invention provides a method of ameliorating inflammation in a patient by administering a therapeutically effective dose of a composition that includes polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. The method specifically targets the removal of inflammatory mediators, such as cytokines, from the intestinal lumen. Another notable patent involves selective targeting agents for mitochondria. This invention includes a composition and related methods for delivering cargo to mitochondria, utilizing a membrane-active peptidyl fragment with a high affinity for mitochondria. The cargo can be selected from a variety of desired substances intended for specific therapeutic purposes, particularly in treating illnesses associated with cellular damage or dysfunction.

Career Highlights

Fink has had a distinguished career, working with esteemed institutions such as the University of Pittsburgh and the Feinstein Institute for Medical Research. His work has focused on innovative solutions to complex medical challenges, particularly in the realm of inflammation and mitochondrial dysfunction.

Collaborations

Throughout his career, Fink has collaborated with notable colleagues, including Kevin J. Tracey and Peter Wipf. These collaborations have further enhanced his research and contributed to the development of impactful medical technologies.

Conclusion

Mitchell P. Fink's innovative work and numerous patents reflect his dedication to advancing medical science and improving patient care. His contributions continue to influence the field and inspire future research endeavors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…